Key Points
- Major shareholder Financial Lp Hrt purchased 14,556 Profusa shares at an average price of $0.96, spending $13,973.76. The transaction increased its direct stake by 15.53% to 108,301 shares.
- The shareholder also bought 1,368 shares on August 4 and 1,310 shares on July 29, continuing a series of recent purchases disclosed in SEC filings.
- Profusa shares opened at $0.94, near their 52-week low of $0.86, while analysts maintain a consensus “Sell” rating.
Profusa, Inc. (NASDAQ:PFSA - Get Free Report) major shareholder Financial Lp Hrt bought 14,556 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average cost of $0.96 per share, for a total transaction of $13,973.76. Following the transaction, the insider directly owned 108,301 shares of the company's stock, valued at $103,968.96. This trade represents a 15.53% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Tuesday, August 4th, Financial Lp Hrt purchased 1,368 shares of Profusa stock. The stock was bought at an average cost of $0.95 per share, with a total value of $1,299.60.
- On Wednesday, July 29th, Financial Lp Hrt purchased 1,310 shares of Profusa stock. The stock was bought at an average price of $1.01 per share, for a total transaction of $1,323.10.
Profusa Price Performance
NASDAQ PFSA opened at $0.94 on Thursday. The company's fifty day moving average is $3.73 and its two-hundred day moving average is $33.53. Profusa, Inc. has a 52-week low of $0.86 and a 52-week high of $1,297.50. The firm has a market capitalization of $178,771.00, a price-to-earnings ratio of -0.00 and a beta of 0.52.
Analyst Upgrades and Downgrades
Several equities analysts have commented on PFSA shares. Wall Street Zen raised Profusa from a "strong sell" rating to a "sell" rating in a report on Saturday, April 18th. Weiss Ratings restated a "sell (e+)" rating on shares of Profusa in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Sell".
Read Our Latest Report on Profusa
About Profusa
(
Get Free Report)
Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.
The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
